Brevan Howard Capital Management LP Erasca, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Erasca, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 90,746 shares of ERAS stock, worth $234,124. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90,746
Previous 122,671
26.02%
Holding current value
$234,124
Previous $155,000
27.1%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ERAS
# of Institutions
156Shares Held
213MCall Options Held
281KPut Options Held
32K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$58.6 Million2.1% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.2MShares$52.2 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$46.1 Million5.91% of portfolio
-
Logos Global Management LP San Francisco, CA15.2MShares$39.1 Million3.82% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$37.4 Million0.95% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $315M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...